Literature DB >> 27904940

[No evidence for improved outcome with salvage radiotherapy for asymptomatic biochemical prostate cancer recurrence after prostatectomy by additive androgen suppression].

Helena Garcia Schüler1, Matthias Guckenberger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27904940     DOI： 10.1007/s00066-016-1082-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.

Authors:  Piet Ost; Nicolaas Lumen; An-Sofie Goessaert; Valérie Fonteyne; Bart De Troyer; Filip Jacobs; Gert De Meerleer
Journal:  Eur Urol       Date:  2011-04-16       Impact factor: 20.096

2.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Authors:  Christian Carrie; Ali Hasbini; Guy de Laroche; Pierre Richaud; Stéphane Guerif; Igor Latorzeff; Stéphane Supiot; Mathieu Bosset; Jean-Léon Lagrange; Véronique Beckendorf; François Lesaunier; Bernard Dubray; Jean-Philippe Wagner; Tan Dat N'Guyen; Jean-Philippe Suchaud; Gilles Créhange; Nicolas Barbier; Muriel Habibian; Céline Ferlay; Philippe Fourneret; Alain Ruffion; Sophie Dussart
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

3.  Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Authors:  Gillian M Duchesne; Henry H Woo; Julie K Bassett; Steven J Bowe; Catherine D'Este; Mark Frydenberg; Madeleine King; Leo Ledwich; Andrew Loblaw; Shawn Malone; Jeremy Millar; Roger Milne; Rosemary G Smith; Nigel Spry; Martin Stockler; Rodney A Syme; Keen Hun Tai; Sandra Turner
Journal:  Lancet Oncol       Date:  2016-05-04       Impact factor: 41.316

4.  Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.

Authors:  Anuj Goenka; Juan Martin Magsanoc; Xin Pei; Michael Schechter; Marisa Kollmeier; Brett Cox; Peter T Scardino; James A Eastham; Michael J Zelefsky
Journal:  Eur Urol       Date:  2011-08-12       Impact factor: 20.096

5.  High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Authors:  Almudena Zapatero; Araceli Guerrero; Xavier Maldonado; Ana Alvarez; Carmen Gonzalez San Segundo; Maria Angeles Cabeza Rodríguez; Victor Macias; Agustí Pedro Olive; Francesc Casas; Ana Boladeras; Carmen Martín de Vidales; Maria Luisa Vazquez de la Torre; Salvador Villà; Aitor Perez de la Haza; Felipe A Calvo
Journal:  Lancet Oncol       Date:  2015-02-19       Impact factor: 41.316

6.  Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

Authors:  Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger
Journal:  J Nucl Med       Date:  2015-03-19       Impact factor: 10.057

7.  Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer.

Authors:  Anusha Kalbasi; Jiaqi Li; Abigail Berman; Samuel Swisher-McClure; Marc Smaldone; Robert G Uzzo; Dylan S Small; Nandita Mitra; Justin E Bekelman
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

8.  Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.

Authors:  Pirus Ghadjar; Stefanie Hayoz; Jürg Bernhard; Daniel R Zwahlen; Tobias Hölscher; Philipp Gut; Matthias Guckenberger; Guido Hildebrandt; Arndt-Christian Müller; Ludwig Plasswilm; Alexandros Papachristofilou; Lukas Stalder; Christine Biaggi-Rudolf; Marcin Sumila; Helmut Kranzbühler; Yousef Najafi; Piet Ost; Ngwa C Azinwi; Christiane Reuter; Stephan Bodis; Khanfir Kaouthar; Peter Wust; George N Thalmann; Daniel M Aebersold
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet Oncol       Date:  2014-02-26       Impact factor: 41.316
  10 in total
  1 in total

1.  [Radiation with additional antiandrogen therapy in recurrent prostate cancer].

Authors:  Stephan Roth
Journal:  Strahlenther Onkol       Date:  2017-08       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.